Advertisement

Knowing the Flip Side of the Coin: Ibrutinib Associated Cystoid Macular Edema

  • Sumeet P. MirghEmail author
  • Rayaz Ahmed
  • Narendra Agrawal
  • Sneha Bothra
  • Bhaarat Mohan
  • Ambar Garg
  • Shinto Francis Thekkudan
  • Vishvdeep Khushoo
  • Dinesh Bhurani
Correspondence
  • 4 Downloads

Dear Editor,

A 62-year-old man, normotensive, non-diabetic, was diagnosed with CLL in October 2009, Rai stage 3, Binet stage B. He was treated initially with chlorambucil monotherapy for 12 months due to symptomatic massive splenomegaly and achieved a partial response. In 2012, he received 6 cycles of Bendamustine–Rituximab (BR) chemoimmunotherapy and achieved a partial response. After 18 months, he presented with a second relapse. Molecular studies (FISH–CLL panel) revealed both 11q and 13q deletion. Patient was initiated on Ibrutinib (Imbruvica) monotherapy. Initially, he tolerated ibrutinib well and achieved a partial response. Due to recurrent sino-nasal infections and low IgG levels (IgG, 203 mg/dl), he received intravenous immunoglobulin 0.4 g/kg monthly for 6 months. After 4 years on ibrutinib, (September 2018), he reported visual blurring, with intermittent flashes of light in both eyes for the previous 1 year. Due to these symptoms, he underwent a left eye cataract surgery;...

Notes

Compliance with Ethical Standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Makri OE, Georgalas I, Georgakopoulos CD (2013) Drug-induced macular edema. Drugs 73:789–802CrossRefGoogle Scholar
  2. 2.
    Saenz-de-Viteri M, Cudrnak M (2019) Bilateral cystoid macular edema in a patient with chronic lymphocytic leukemia treated withibrutinib. LeukLymphoma 60(3):842–844Google Scholar
  3. 3.
    Farooqui MZH, Valdez J, Martyr S et al (2015) Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial. Lancet Oncol 16:169–176CrossRefGoogle Scholar
  4. 4.
    Bernard S, Goldwirt L, Amorim S et al (2015) Activity of ibrutinib in mantle cell lymphoma patients with central nervous systemrelapse. Blood 126:1695–1698CrossRefGoogle Scholar
  5. 5.
    Byrd JC, Brown JR, O’Brien S, Barrientos JC, Kay NE, Reddy NM, Coutre S et al (2014) Ibrutinib versus ofatumumab in previously treated chronic lymphocytic leukemia. N Engl J Med 371:213–223CrossRefGoogle Scholar
  6. 6.
    Shaikh H, Khattab A, Faisal MS, Chilkulwar A, Albrethsen M, Sadashiv S, Fazal S (2018) Case series of unique adverse events related to the use of ibrutinib in patients with B-cell malignancies—a single institution experience and a review of literature. J Oncol Pharm Pract 25:1078155218788707Google Scholar

Copyright information

© Indian Society of Hematology and Blood Transfusion 2019

Authors and Affiliations

  1. 1.Department of HematologyRajiv Gandhi Cancer InstituteNew DelhiIndia
  2. 2.Parel, MumbaiIndia

Personalised recommendations